- TRADE NAME: Livmarli (Mirum Pharma)
- INDICATIONS: Treatment of cholestatic pruritus in patients with Alagille syndrome.
- CLASS: Bile acid transporter inhibitor
- HALF-LIFE: 1.6 hours
- FDA APPROVAL DATE: 09/28/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bile acid binding resins, Cholestyramine, Statins - PREGNANCY: Maternal use at the recommended clinical dose of maralixibat is not expected to result in measurable fetal exposure because systemic absorption following oral administration is low.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
